Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
J ANTIINFECTIVES FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
J05A DIRECT ACTING ANTIVIRALS
J05AE Protease inhibitors
J05AE05 Amprenavir
D00894 Amprenavir (JAN/USAN/INN)
Drug groups [BR:br08330]
Antiviral
DG03107 Anti-HIV agent
DG01647 HIV protease inhibitor
D00894 Amprenavir
Metabolizing enzyme substrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
D00894 Amprenavir
Metabolizing enzyme inhibitor
DG02852 CYP3A/CYP3A4 inhibitor
D00894 Amprenavir
Metabolizing enzyme inducer
DG02853 CYP3A/CYP3A4 inducer
D00894 Amprenavir
Antimicrobials [BR:br08307]
Antivirals
Polyprotein cleavage inhibitor
HIV protease inhibitor
D00894 Amprenavir (JAN/USAN/INN)
Antimicrobials abbreviations [BR:br08327]
Antivirals
Polyprotein cleavage inhibitor
HIV protease inhibitor
D00894 Amprenavir (JAN/USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D00894
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D00894
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D00894
Prodrugs [br08324.html]
D00894